Literature DB >> 31926702

Antiplatelet therapy abrogates platelet-assisted Staphylococcus aureus infectivity of biological heart valve conduits.

Bartosz Ditkowski1, Martyna Bezulska-Ditkowska2, Ramadan Jashari3, Pieter Baatsen4, Philippe Moreillon5, Filip Rega6, Tiago R Veloso1, Marc F Hoylaerts7, Ruth Heying8.   

Abstract

OBJECTIVE: Although recent advances in pulmonary valve replacement have enabled excellent hemodynamics, infective endocarditis remains a serious complication, particularly for implanted bovine jugular vein (BJV) conduits.
METHODS: We investigated contributions by platelets and plasma fibrinogen to endocarditis initiation on various grafts used for valve replacement. Thus, adherence of Staphylococcus aureus and platelets to 5 graft tissues was studied quantitatively in perfusion chambers, assisted by microscopic analysis. We also evaluated standard antiplatelet therapy to prevent onset of S aureus endocarditis.
RESULTS: Of all tissues, bovine pericardium (BP) showed the greatest fibrinogen binding. Perfusion of all plasma-precoated tissues identified BP and BJVwall with the greatest affinity for S aureus. Perfusions of anticoagulated human blood over all tissues also triggered more platelet adhesion to BP and BJVwall as single platelets. Several controls confirmed that both S aureus and platelets were recruited on immobilized fibrinogen. In addition, perfusions (and controls) over plasma-coated tissues with whole blood, spiked with S aureus, revealed that bacteria exclusively bound to adhered platelets. Both the platelet adhesion and platelet-mediated S aureus recruitment required platelet αIIbβ3 and coated or soluble fibrinogen, respectively, interactions abrogated by the αIIbβ3-antagonist eptifibatide. Also, standard antiplatelet therapy (aspirin/ticagrelor) reduced the adherence of S aureus in blood to BJV 3-fold.
CONCLUSIONS: Binding of plasma fibrinogen to especially BJV grafts enables adhesion of single platelets via αIIbβ3. S aureus then attaches from blood to (activated) bound platelet αIIbβ3 via plasma fibrinogen. Dual antiplatelet therapy appears a realistic approach to prevent endocarditis and its associated mortality.
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  S aureus; cardiac graft tissues; fibrinogen; infective endocarditis; platelets

Mesh:

Substances:

Year:  2019        PMID: 31926702     DOI: 10.1016/j.jtcvs.2019.10.188

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Non-Antimicrobial Adjuvant Therapy Using Ticagrelor Reduced Biofilm-Related Staphylococcus aureus Prosthetic Joint Infection.

Authors:  Narayan Pant; Socorro Miranda-Hernandez; Catherine Rush; Jeffrey Warner; Damon P Eisen
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 2.  Antiplatelet therapy for Staphylococcus aureus bacteremia: Will it stick?

Authors:  Alexander M Tatara; Ronak G Gandhi; David J Mooney; Sandra B Nelson
Journal:  PLoS Pathog       Date:  2022-02-10       Impact factor: 6.823

Review 3.  Infective Endocarditis in High-Income Countries.

Authors:  Francesco Nappi; Giorgia Martuscelli; Francesca Bellomo; Sanjeet Singh Avtaar Singh; Marc R Moon
Journal:  Metabolites       Date:  2022-07-25

4.  The role of antiaggregant agents and anticoagulants in the prevention of aortic valve endocarditis: A double-cohort retrospective study.

Authors:  Hanne Theys; Jef Van den Eynde; Marie-Christine Herregods; Philippe Moreillon; Ruth Heying; Wouter Oosterlinck
Journal:  JTCVS Open       Date:  2021-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.